Objective: To provide long-term data on survival and major morbidity after mitral valve replacement in patients aged 18 to 50 years. 
Results: Bioprosthetic valve use increased from 10% to 34% between 1997 and 2014 (P < .001). Among propensity score-matched patients, actuarial 15 
Conclusions:
The significant survival benefit associated with mechanical mitral valve replacement in adults 50 years may be due to the practice of implanting bioprostheses in sicker patients or those judged less likely to comply with long-term medication despite adjustment for baseline characteristics in propensity score matching. (J Thorac Cardiovasc Surg 2018;155:96-102)
Survival in propensity-matched adults aged 50 years according to mitral prosthesis type.
Central Message
In patients aged 18 to 50 years, bioprosthetic mitral valve replacements are used increasingly often but are associated with lower survival at 15 years compared with mechanical valves.
Perspective
Bioprosthetic mitral valve use has increased in patients aged 18 to 50 years despite few supporting data. We observed worse survival and freedom from reoperation, without a benefit in freedom from stroke or bleeding, compared with mechanical valves. This may reflect differences in bioprosthesis durability or patient characteristics and should be taken into account during preoperative decision-making.
See Editorial Commentary page 103.
See Editorial page 79.
Approximately 10% of patients undergoing mitral valve replacement in the United States are adults <50 years of age. 1 Current consensus guidelines favor mechanical over bioprosthetic valve replacement in this age group because the risks of structural valve degeneration and reoperation associated with bioprostheses are thought to outweigh the increased risk of hemorrhagic and embolic events associated with mechanical valves and life-long anticoagulation. 2, 3 These recommendations are based primarily on the results of 2 randomized controlled trials that found no significant difference in late survival [4] [5] [6] but that were performed during the 1970s and 1980s in older patients who predominantly underwent aortic rather than mitral valve replacement and on more recent,
Study Endpoints
All-cause mortality was the primary outcome, and the secondary outcomes were stroke, major bleeding, and mitral valve reoperation. Deaths were captured from California and New York State Vital Death Records via their respective Departments of Health. Additional death records were collected from the discharge disposition from any subsequent inpatient, emergency department, or ambulatory surgery visits, as well as from the Social Security Death Master File. Stroke during the index admission was defined as a postoperative cerebrovascular accident and in subsequent admissions as a primary diagnosis of ischemic or hemorrhagic cerebrovascular event. Transient ischemic attacks were excluded from this definition. Major bleeding was defined as a primary diagnosis of any bleeding event that required admission to hospital. Reoperation was defined as mitral valve replacement in subsequent admissions. ICD-9-CM codes were used to identify these late events (Tables E3 and E4 ). Patients free from death, stroke, major bleeding, or reoperation were censored on December 31, 2014.
Statistical Analysis
Means with standard deviations are used to report continuous variables, and proportions are used to report categorical variables. The Student t test for normally distributed continuous variables and Pearson c 2 test for categorical variables as well as standardized differences for both continuous and categorical variables were used to quantify the differences in baseline characteristics between patients receiving bioprosthetic and mechanical prosthetic mitral valves. The Kolmogorov test was used to determine normality in continuous variables. Non-normal continuous variables are reported as median with interquartile ranges, and differences were tested via the Wilcoxon-Mann-Whitney test. Trend analysis was performed with the Cochran-Armitage test on patients receiving mitral valve replacements between January 1, 1997, and December 31, 2014.
To eliminate confounding due to intrinsic differences in baseline characteristics between the bioprosthetic and mechanical valve replacement cohorts, propensity score matching was performed. Propensity scores were calculated with a logistic regression with bioprosthetic valve implantation as the outcome and all patient baseline characteristics (admission urgency, index surgery year, age, sex, race, coagulation defects, hypertension, diabetes, coronary artery disease, peripheral vascular disease, cerebrovascular disease, congestive heart failure, atrial fibrillation, chronic obstructive pulmonary disease, chronic kidney disease, liver disease, cancer) included in the model as covariates. 13, 14 The area under the receiver operating characteristic curve for the model was 0.78. Patients were then matched 1:1 using a caliper of 0.01 of the logit of the propensity score. Differences in baseline characteristics and 30-day complication incidence between patients in both groups were detected with the use of the paired t test for normally distributed continuous variables, the Wilcoxon signed rank sum test for non-normally distributed continuous variables, and the McNemar test for categorical variables; standardized differences were also reported.
Survival curves of the primary outcome of mortality were constructed with the Kaplan-Meier method; prostheses were compared with a marginal Cox model with a robust sandwich variance estimator.
Competing risk analysis of the secondary outcomes-stroke, major bleeding, and reoperation-was performed by creating cumulative incidence functions. For each end point, adjusted hazard ratios were calculated with Cox proportional hazards models. The proportional hazards assumption was assessed in each model and found to be intact except reoperation and, if violated, the hazard ratios at different follow-up time points were reported.
To assess the robustness of the findings, all analyses were repeated in the full patient cohort as a sensitivity analysis using multivariable analysis with marginal Cox models with robust sandwich variance estimators controlling for admission urgency, index surgery year, age, sex, race, coagulation defects, hypertension, diabetes, coronary artery disease, peripheral vascular disease, cerebrovascular disease, congestive heart failure, atrial fibrillation, chronic obstructive pulmonary disease, chronic kidney disease, liver disease, cancer, and clustering of patients within hospitals. All these sensitivity analyses confirmed the main findings and were included in the supplementary documents (Table E5 ).
All statistical tests were 2-tailed and an alpha level of 0.05 considered statistically significant. Statistical analyses were carried out with SAS version 9.4 (SAS Institute Inc, Cary, NC).
RESULTS

Study Population
We identified 5818 patients aged 18 to 50 years who underwent mitral valve replacement. After excluding patients from out-of-state (4.9%, n ¼ 282) and with previous valve replacement or repair (6.8%, n ¼ 398), previous heart transplant (<0.3%, n < 15), concomitant valve replacement or repair (26.1%, n ¼ 1520), congenital cardiac history or procedure (2.5%, n ¼ 145), endocarditis (18.8%, n ¼ 1095), and concomitant coronary artery bypass grafting (9.4%, n ¼ 544), the study cohort 
Patient Characteristics
Use of bioprosthetic mitral replacements increased from 10.1% in 1997 to 33.6% in 2014 (P <.001; Figure E1 ). Patients who received bioprosthetic valves had a greater prevalence of emergent/urgent admission (39.0% vs 26.6%, P<.001) but a lower prevalence of atrial fibrillation (24.6% vs 34.8%, P <.001) (Table E6 ). In the propensity score-matched groups, there were no significant differences in patient characteristics (Table 1) or 30-day outcomes after bioprosthetic versus mechanical valve replacement, suggesting that these groups were well matched ( Table 2) .
Survival
We observed a significant difference in long-term survival between bioprosthetic and mechanical mitral valves in the propensity score-matched groups (Figure 1 (Table E5 ). In analysis of each age group, no survival benefit was observed in mechanical valve between age 18 to 30 and 31 to 40 years, but patients who had mechanical valve had significantly better survival than patients with bioprosthetic valve between age 41 and 50 ( Figure E2 ).
Stroke
There was no significant difference in the risk-adjusted cumulative incidence of stroke between bioprosthetic and mechanical mitral valves at 15 years in the propensity score-matched cohort. In the propensity score-matched cohort, the cumulative incidence of stroke at 5, 10, and 15 years was 4.8% (95% CI, 3.0%-7.3%), 7.1% (95% CI, 4.8%-10.0%), and 9.1% (95% CI, 6.0%-13.0%) in patients who underwent bioprosthetic mitral valve replacement versus 5.4% (95% CI, 3.4%-8.0%), 8.9% (95% CI, 6.2%-12.1%), and 9.7% (95% CI, 6.7%-13.4%) in patients who underwent mechanical mitral valve replacement, respectively (HR, 0.95; 95% CI, 0.57-1.59) (Figure 2 , A). The 30-day mortality after stroke was 5.3%. The results of the multivariable analysis of stroke in the full patient cohort are shown in Table E5 .
Major Bleeding
There was no significant difference in the risk-adjusted cumulative incidence of major bleeding between bioprosthetic and mechanical valves at 15 years in the propensity score-matched cohort. The cumulative incidence of bleeding in the overall cohort at 5, 10, and 15 years was 4.3% (95% CI, 2.6%-6.7%), 5.9% (95% CI, 3.8%-8.6%), and 7.9% (95% CI, 5.0%-11.5%) in patients who underwent bioprosthetic mitral valve replacement versus 4.6% (95% CI, 2.8%-7.0%), 8.4% (95% CI, 5.8%-11.6%), and 11.5% (95% CI, 7.6%-16.2%) in patients who underwent mechanical mitral valve replacement, respectively (HR, 0.78; 95% CI, 0.46-1.32) (Figure 2 , B). The 30-day mortality after major bleeding was 6.8%. The results of the multivariate analysis of major bleeding in the full patient cohort are shown in Table E5 .
Reoperation
Mechanical valves were associated with a significantly lower rate of mitral valve reoperation than bioprosthetic valves in the propensity score-matched cohort. The cumulative incidence of mitral valve reoperation in the propensity score-matched cohort at 5, 10, and 15 years in patients with bioprosthetic mitral valves was 4.6% (95% CI, 2.8%-7.0%), 14.1% (95% CI, 10.6%-18.0%), and 19.9% (95% CI, 15.4%-24.8%) versus 2.7% (95% CI, 1.4%-4.7%), 4.7% (95% CI, 2.8%-7.2%), and 5.7% (95% CI, 3.5%-8.7%) in patients with mechanical valves, respectively (adjusted HR at 15 years 20.3; 95% CI, 4.0-102.8) (Figure 2, C) . An overall 30-day mortality after reoperation was 2.5%. The results of the multivariable analysis of reoperation in the full patient cohort are shown in Table E5 .
DISCUSSION
This study provides long-term data on survival and major morbidity after mitral valve replacement in young adults from a broad cross-section of contemporary clinical practice. Our data show first that up to one third of patients aged 50 years undergoing mitral valve replacement receive bioprosthetic valves and second the much greater risk of reoperation does not appear to be offset by any reduction in stroke and major bleeding rates compared with mechanical valves. The poorer survival that we observed in patients who received bioprosthetic valves confirms the findings of much smaller retrospective studies. [9] [10] [11] Studies comparing bioprosthetic with mechanical mitral valve replacement in this age group previously have been FIGURE 2. Cumulative incidence of major morbidity in propensity score-matched patients aged 18 to 50 years after mitral valve replacement according to prosthesis type: A, stroke; B, major bleeding; and C, reoperation. HR, Hazard ratio; CI, confidence interval.
limited to single-center retrospective studies, with conflicting results regarding both the comparative risks of reoperation and survival. For example, Kaneko and colleagues 10 reported better survival and freedom from reoperation at 15 years with mechanical mitral valve replacement over bioprosthetic in 125 propensity-matched patients pairs <65 years of age, whereas others have observed no significant differences in long-term survival. 8, 12 The comprehensive patient level data and large size of our cohort, which represents contemporary practice across 2 large states and 171 institutions, allowed us to adjust for key patient and provider characteristics, confirmed by the very similar 30-day outcomes in the mechanical and bioprosthetic propensity score-matched patient groups.
There are several potential explanations for our observation of a survival benefit with mechanical mitral valves. First, despite propensity matching, the likelihood remains that we are comparing substantially different patient populations. This is because of the established practice of implanting bioprosthetic valves in patients with reduced life expectancy or in patients judged unlikely to comply with life-long anticoagulation.
2,3 Without patient-level data on these specific aspects of decision making, these important factors cannot be adjusted for retrospectively, potentially explaining why smaller retrospective studies show significantly worse survival in recipients of bioprosthetic valves.
The second potential reason for the reduced survival associated with bioprosthetic valves is the accelerated structural valve degeneration seen in the mitral position in younger patients. 6 This means that young patients with bioprosthetic mitral valves bear an earlier burden of severe valvulopathy and reoperation which, in the absence of any survival benefits from reduced stroke and major bleeding events, may be an important determinant of their worse survival. In our propensity score-matched cohort, the cumulative incidence of reoperation was 19.9% in bioprosthetic patients versus 5.7% in mechanical patients. These results are well known: Kaneko and colleagues, 10 Carrel and colleagues, 7 and Ruel and colleagues 15 all report high rates of structural valve degeneration and replacement among these younger patients. The implications of these data are greatest for patients unable or unwilling to comply with long-term anticoagulation. The commonest reasons for this in young patients are difficulty accessing health care and child-bearing, rather than comorbid contraindications to anticoagulation. 16 These considerations are particularly relevant for patients from low-and middle-income countries where rheumatic valve disease is more prevalent in young women and long-term access to health care is less readily available. 17 For many patients without reliable access to health care, and particularly those considering pregnancy, the immediate safety profile of bioprosthetic valves outweighs the risks posed by accelerated structural degeneration. Although these bioprosthetic valves are accompanied by significantly high rates of reoperation, only the placement of a bioprosthetic valve will allow for a potential future valve-in-valve replacement. It would be difficult to counsel patients on the merits of a bioprosthetic valve in the hopes of a future valve-in-valve rescue, as this emerging technology's applicability and durability remain to be seen in younger, lower-risk patients. 18 
Limitations
Although this study represents a broad sample of contemporary practice in North America and provides valuable long-term outcome data, there are substantial limitations in how these data can be interpreted. This is primarily because, as described previously, selection bias cannot be adequately controlled for retrospectively in young patients undergoing mitral valve replacement without more information on the rationale for valve choice. Residual confounding may exist even after propensity score matching. Second, the data are abstracted from clinical records by administrative coders and provide limited information on the etiology, severity, and sequelae of valve disease and comorbidities and no data on the model or size of each valve prosthesis beyond whether it is mechanical or bioprosthetic. Third, the number of patients at risk at 15 years is relatively small. Fourth, we may have underestimated the rate of the secondary endpoints because identifying them depends on patients remaining within their state; nevertheless, we believe that this equally affects both groups and does not diminish the study's comparative value. Finally, the follow-up available to us does not fully represent the relative lifetime risks in this patient age group. Combining this with data from additional states or national clinical datasets may allow a more definitive analysis of outcomes in this patient population that is likely to remain underrepresented in clinical trials.
CONCLUSIONS
In adults 50 years who undergo mitral replacement, the much greater risk of reoperation with bioprosthetic valves is not mitigated by a reduction in stroke and major bleeding rates compared to mechanical valves. The significant survival benefit that we observed with mechanical mitral valve replacement may be due to accelerated structural degeneration in mitral bioprostheses. These findings should inform decision-making in patients, particularly those basing prosthesis selection on lifestyle choices rather than access to health care or contraindications to lifelong anticoagulation.
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